EPISODE · Jul 11, 2025 · 31 MIN
Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)
from BiotechTV - News · host BiotechTV
Jorge Santos da Silva walks us through the scientific design of the molecule, which is a nanobody that binds to IL-17A, IL-17F, and albumin. He compares and contrasts it to key competitor BIMZELX and describes what the company is hoping to see in the trial readout. Plus, commercial plans, pipeline, and more.
Embed this episode
Ready to play
Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.